Functional and structural abnormalities in the nerves of Type I diabetic baboons: Aminoguanidine treatment does not improve nerve function

Diabetologia

Volumn 43, Issue 1, 2000, Pages 110-116

  Birrell, A M ^a   Heffernan, S J ^b   Ansselin, A D ^b   McLennan, S ^b   Church, D K ^b   Gillin, A G ^a   Yue, D K ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b NONE

Author keywords

Advanced glycation end products; Aminoguanidine; Autonomic; Diabetic complications; Monkey; Morphometry; Myelin; Nerve conduction velocity; Neuropathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; HEMOGLOBIN A1C; INSULIN; STREPTOZOCIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BABOON; CONTROLLED STUDY; DIABETIC NEUROPATHY; HEART RATE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MORPHOMETRICS; NERVE; NERVE CONDUCTION; NERVE FUNCTION; NONHUMAN; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

EID: 0034011172     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050014     Document Type: Article

References (44)

1. 1. Orchard T, Dorma J, Maser R et al. (1990) Factors associated with avoidance of severe complications after 25 years of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 13: 741-747
2. 2. Clarke C Neuropathy. In: Werther GA and Court JM (eds), Diabetes and the Adolescent. Miranova Publishers, Camberwell, pp 175-189
3. 3. DCCT (1988) Factors in development of diabetic neuropathy: Baseline analysis in neuropathy in feasibility phase of diabetes control and complications trial (DCCT). Diabetes 37: 476-481
4. 4. Cameron NE, Cotter MA (1997) Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 46 [Suppl 2]:S31-S37
5. 5. Ward J (1997) Upright posture and the microvasculature in human diabetic neuropathy: a hypothesis. Diabetes 46 [Suppl 2]: S94-S97
6. 6. Ward J (1999) Improving Prognosis in Type 2 Diabetes: Diabetic neuropathy in trouble. Diabetes Care 22: B84-B88
7. 7. Low PA, Nickander KK, Tritschler HJ (1997) The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 46 [Suppl 2]: S38-S42
8. 8. Amthor KF, Dahl-Jorgensen K, Berg TJ et al. (1994) The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study. Diabetologia 37: 579-584
9. 9. Ringel RE, Chalew SA, Armour KA et al. (1993) Cardiovascular reflex abormalities in children and adolescents with diabetes mellitus. Diabetes Care 16: 734-741
10. 10. Sugimura K, Dyck PJ (1981) Sural nerve myelin thickness and axis cylinder caliber in human diabetes. Neurology 31: 1087-1091
11. 11. Britland ST, Young RJ, Sharma AK, Clarke BF (1990) Association of painful and painless diabetic polyneuropathy with different patterns of nerve fibre degeneration and regeneration. Diabetes 39: 898-908
12. 12. Malik RA (1997) The pathology of human diabetic neuropathy. Diabetes 46 [Suppl 2]:S50-S53
13. 13. Malik RA (1998) The Primary Pathology and Pathogenesis of Human Diabetic Neuropathy. Diabetologia 41 [Suppl 1] A50 (Abstract)
14. 14. Malone JI, Lowitt S, Korthals JK, Salem A, Miranda C (1996) The effect of hyperglycemia on nerve conduction and structure is age dependent. Diabetes 45: 209-215
15. 15. Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321
16. 16. Vlassara H (1997) Recent progress in advanced glycation end products and diabetic complications. Diabetes 46 [Suppl 2]:S19-S25
17. 17. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632
18. 18. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K (1992) Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 41: 47-52
19. 19. Miyauchi Y, Shikama H, Takasu T et al. (1996) Slowing of peripheral motor nerve conduction was ameliorated by amino-guanidine in streptozocin-induced diabetic rats. Eur J Endocrinol 134: 467-473
20. 20. Cameron NE, Cotter MA (1996) Rapid reversal by aminoguanidine of the neurovascular effects of diabetes in rats: modulation by nitric oxide synthase inhibition. Metabolism 45: 1147-1152
21. 21. Schmidt RE, Dorsey DA, Beaudet LN et al. (1996) Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in the superior mesenteric sympathetic autonomie ganglia of rats with streptozocin-induced diabetes. Diabetes 45: 284-290
22. 22. Dewhurst M, Omawari N, Tomlinson DR (1997) Aminoguanidine: effects on endoneurial vasoactive nitric oxide and on motor nerve conduction velocity in control and streptozotocin-diabetic rats. Br J Pharmacol 120: 593-598
23. 23. Heffernan S, Phippard A, Sinclair A et al. (1995) A baboon (Papio hamadryas) model of insulin-dependent diabetes. J Med Primatol 24: 29-34
24. 24. Maclean JM, Phippard AF, Garner MG et al. (1987) Group housing of hamadryas baboons: a new cage design based upon field studies of social organization. Lab Anim Sci 37: 89-93
25. 25. Holmes KA, Paull MD, Birrell AM et al. (1996) A unique design for ease of access and movement of captive Papio hamadryas. Lab Anim 30: 327-331
26. 26. Beaven MA, Gordon JW, Jacobsen S, Severs WB (1969) A specific and sensitive assay for aminoguanidine: its application to a study of the disposition of aminoguanidine in animal tissue. J Pharmacol Exp Ther 165: 14-22
27. 27. Kimura J (1980) Principles of nerve conduction studies. Electrodiagnosis in Diseases of nerves and muscle; Principles and practice. FA Davis, Philadelphia, pp 83-103
28. 28. Phippard A, Maclean J, Garner M, Horvath J (1987) Systemic und pulmonary haemodynamics during continuous ketamine infusions in baboons. Australian Primatology 2: 4-6
29. 29. Goosen DJ, Davies JH, Maree M, Dormehl IC (1984) The influence of physical and chemical restraint on the physiology of the chacma baboon (Papio ursinus). Journal of Medical Primatology 13: 339-351
30. 30. Ansselin AD, Davey DF (1993) The regeneration of axons through normal and reversed nerve grafts. Restorative neurology and neuroscience 5: 225-240
31. 31. Gundersen HJG (1977) Notes on the estimation of the numerical density of arbitary profiles: The edge effect. J Microsc 111: 219-223
32. 32. Howard CF Jr (1982) Nonhuman primates as models for the study of human diabetes mellitus. Diabetes 31: 37-42
33. 33. Yasuda H, Harano Y, Kosugi K et al. (1984) Development of early lesions of microangiopathy in chronically diabetic monkeys. Diabetes 33: 415-420
34. 34. Cornblath DR, Hillman MA, Striffler JS, Herman CN, Hansen BC (1989) Peripheral neuropathy in diabetic monkeys. Diabetes 38: 1365-1370
35. 35. Jakobsen J, Sidenius P (1985) Nerve morphology in experimental diabetes. Clin Physiol [Suppl 5]: S9-S13
36. 36. Sharma AK, Bajada S, Thomas PK (1981) Influence of streptozotocin-induced diabetes on myelinated nerve fibre maturation and on body growth in the rat. Acta Neuropathol (Berl) 53: 257-265
37. 37. Llewelyn JG, Gilbey SG, Thomas PK et al. (1991) Sural nerve morphometry in diabetic autonomie and painful sensory neuropathy. A clinicopathological study. Brain 114: 867-892
38. 38. Donaghue KC (1998) Autonomie neuropathy: diagnosis and impact on health in adolescents with diabetes. Horm Res 50 [Suppl 1]: S33-S37
39. 39. Alteon (1998) Database: www.alteonpharma.com
40. 40. Way KJ, Reid JJ (1994) Effect of aminoguanidine on the impaired nitric oxide-mediated neurotransmission in anococcygeus muscle from diabetic rats. Neuropharmacology 33: 1315-1322
41. 41. Cameron NE, Cotter MA, Dines K, Love A (1992) Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 35: 946-950
42. 42. Wada R (1999) Only limited effects of aminoguanidine treatment on peripheral nerve function, (Na, K)-ATpase activity and thromobomodulin expression in streptozotocin-induced diabetic rats. Diabetologia 42: 743-747
43. 43. Hammes HP, Strodter D, Weiss A et al. (1995) Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 38: 656-660
44. 44. Foote EF, Look ZM, Giles P, Keane WF, Halstenson CE (1995) The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis. Am J Kidney Dis 25: 420-425